WO2001034134A3 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
WO2001034134A3
WO2001034134A3 PCT/US2000/030894 US0030894W WO0134134A3 WO 2001034134 A3 WO2001034134 A3 WO 2001034134A3 US 0030894 W US0030894 W US 0030894W WO 0134134 A3 WO0134134 A3 WO 0134134A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
oncolytic
combinations
oncolytic combinations
Prior art date
Application number
PCT/US2000/030894
Other languages
French (fr)
Other versions
WO2001034134A2 (en
Inventor
Jason Scott Sawyer
Beverly Ann Teicher
Roger Stuart Benjamin
Original Assignee
Lilly Co Eli
Jason Scott Sawyer
Beverly Ann Teicher
Roger Stuart Benjamin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jason Scott Sawyer, Beverly Ann Teicher, Roger Stuart Benjamin filed Critical Lilly Co Eli
Priority to AU15951/01A priority Critical patent/AU1595101A/en
Publication of WO2001034134A2 publication Critical patent/WO2001034134A2/en
Publication of WO2001034134A3 publication Critical patent/WO2001034134A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Leukotriene (LTB4) antagonists enhance the effectiveness of 2',2'-difluoronucleoside anti-cancer agents.
PCT/US2000/030894 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer WO2001034134A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15951/01A AU1595101A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16471699P 1999-11-11 1999-11-11
US60/164,716 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034134A2 WO2001034134A2 (en) 2001-05-17
WO2001034134A3 true WO2001034134A3 (en) 2002-02-14

Family

ID=22595775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030894 WO2001034134A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (2)

Country Link
AU (1) AU1595101A (en)
WO (1) WO2001034134A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
DE10323279A1 (en) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Ready-to-use gemcitabine solutions
DE10359828A1 (en) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP gemcitabine combination agents and their use as antitumor agents, in particular anti-metastatic agents
EP1745800A4 (en) * 2004-04-26 2009-11-18 Ono Pharmaceutical Co Novel blt2-mediated disease, and blt2 binding agent and compound
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2019109147A1 (en) * 2017-12-06 2019-06-13 Omara Stephen Kenneth Methods of treating cancer with leukotriene receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
AU1595101A (en) 2001-06-06
WO2001034134A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2001034137A3 (en) Oncolytic combinations for the treatment of cancer
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
AU7834500A (en) Well treatment fluids comprising mixed aldehydes
ZA200006042B (en) Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections.
HK1051193A1 (en) (1,4')-Bipiperidine compounds.
ZA200202461B (en) Compounds for the treatment of ischemia.
DZ3165A1 (en) Food or pharmaceutical composition used to prevent or treat hyperoxaluria.
MXPA02002086A (en) Metalcontaining compositions, preparations and uses.
ZA200204325B (en) Area Denial.
ZA200108012B (en) Method of enhancing the efficacy of anti-tumor agents.
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
MXPA01008188A (en) Processes and intermediates for the preparation of 1,3-oxazin-6-ones and uracils.
ITRE990028A0 (en) CHELATED FOOD SUPPLEMENT FOR AGRO-ZOOTECHNICAL USE, AND METHOD FOR OBTAINING THE SAME.
ZA200201521B (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparation containing the same, and methods of using the same.
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
AU1917101A (en) Oncolytic combinations for the treatment of cancer
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200002343B (en) Combination therapy for the treatment of migraine.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase